Wenning Qin
Senior Vice President - Research eGenesis Bio
Wenning Qin is Senior Vice President of Research at eGenesis, where she leads efforts in gene editing for xenotransplantation. With a background in molecular biology, she focuses on engineering the porcine genome to enable the safe use of pig organs in human therapies. Her work addresses key molecular incompatibilities between porcine and human systems, aiming to improve organ compatibility and therapeutic efficacy. Dr. Qin’s research is central to advancing innovative solutions for patients suffering from organ failure and critical shortages in transplantable organs worldwide.
Seminars
Wednesday 30th September 2026
Fireside Chat: Transitioning Gene Editing Therapeutics from Bespoke Treatments to Platform Approaches for Broader Disease Indications & Commercial Sustainability
9:00 am
- Identifying strategic, regulatory, and technical barriers limiting gene editing therapeutics to rare, single-patient applications and exploring pathways to expand into larger patient populations
- Examining how industry leaders are navigating manufacturing challenges, clinical development efficiency, and regulatory alignment to make genome editing commercially viable across multiple indications
- Discussing the organizational capabilities, investment priorities, and platform design decisions required to transition from boutique therapies to scalable, multi-disease treatment models
